Table 5.
Risk of cardiovascular diseases in the two drug groups after matching between 2015 and 2018 (without cardiovascular disease history)
| Classification | Febuxostat (24,952 patients) | Allopurinol (24,952 patients) | HR (95% CI) | ||||
|---|---|---|---|---|---|---|---|
| Number of patients (n) | Person–years | Incidence rate (1,000 person –years) | Number of patients (n) | Person–years | Incidence rate (1,000 person –years) | ||
| Primary outcome variable* | |||||||
| Cardiovascular disease | 531 | 22,964.2 | 23.1 | 772 | 37,606.7 | 20.5 | 1.11 (0.99–1.24) |
| Secondary outcome variable | |||||||
| Myocardial infarction | 51 | 23,349.7 | 2.2 | 75 | 38,356.3 | 2.0 | 1.09 (0.76–1.57) |
| Ischemic heart disease | 145 | 23,289.0 | 6.2 | 227 | 38,192.3 | 5.9 | 1.02 (0.83–1.27) |
| Stroke | 131 | 23,286.3 | 5.6 | 209 | 38,229.8 | 5.5 | 1.06 (0.85–1.33) |
| Transient ischemic attack | 56 | 23,338.0 | 2.4 | 85 | 38,342.4 | 2.2 | 1.06 (0.75–1.49) |
| Heart failure | 247 | 23,190.6 | 10.7 | 326 | 38,106.3 | 8.6 | 1.21 (1.02–1.44) |
| Coronary revascularization (treatment) | 26 | 23,368.6 | 1.1 | 45 | 38,388.6 | 1.2 | 0.88 (0.52–1.49) |
| All-cause death | 3 | 22,964.2 | 0.1 | 5 | 37,606.7 | 0.1 | 1.38 (0.31–6.23) |
Note 1) * All-cause death: includes 3 and 5 patients in the febuxostat and allopurinol groups, respectively
Note 2) Coronary revascularization is a treatment code that has secondary outcome variables and overlapping values